CDK4 and neoplasm: To test our hypothesis, we conducted an open-label, multicenter clinical trial and mapped functional activation and signaling architecture of pretreatment tumor tissue biopsies collected from HR+/HER2− MBC patients receiving first-line treatment with a CDK4/6 inhibitor plus ET.